Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;28(6):1023-35.
doi: 10.1016/j.hoc.2014.08.003. Epub 2014 Oct 3.

Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease

Rachel B Salit  1 , H Joachim Deeg  2
Affiliations
Review

Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease

Rachel B Salit et al. Hematol Oncol Clin North Am. 2014 Dec.

Abstract

Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders. While some MPN patients have an indolent course, all are at risk of progressing to severe marrow failure or transforming into acute leukemia. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potential curative therapy. Major pre-transplant risk factors are disease stage of the MPN, the presence of comorbid conditions and the use of HLA non-identical donors. The development of reduced-intensity conditioning regimens has allowed for successful allo-HCT even for older patients and patients with comorbid conditions. The pre-transplant use of JAK2 inhibitors, which may be effective in down staging a patient's disease, may improve the outcomes following allo-HCT.

Keywords: Essential thrombocythemia; Hematopoietic stem cell transplantation; Myelofibrosis; Myeloproliferative neoplasms (MPN); Polycythemia vera; Ruxolitinib.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–8. - PubMed
    1. Tefferi A. How I treat myelofibrosis. Blood. 2011;117:3494–504. - PubMed
    1. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222–30. - PubMed
    1. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–35. - PubMed
    1. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356–63. - PubMed

Publication types

MeSH terms